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Satellite cells are dormant progenitors located at the periphery of skeletal myofibers that can be triggered 
to proliferate for both self-renewal and differentiation into myogenic cells. In addition to anatomic location, 
satellite cells are typified by markers such as M-cadherin, Pax7, Myf5, and neural cell adhesion molecule-1. 
The Pax3 and Pax7 transcription factors play essential roles in the early specification, migration, and myo-
genic differentiation of satellite cells. In addition to muscle-committed satellite cells, multi-lineage stem cells 
encountered in embryonic, as well as adult, tissues exhibit myogenic potential in experimental conditions. 
These multi-lineage stem cells include side-population cells, muscle-derived stem cells (MDSCs), and mesoan-
gioblasts. Although the ontogenic derivation, identity, and localization of these non-conventional myogenic 
cells remain elusive, recent results suggest their ultimate origin in blood vessel walls. Indeed, purified peri-
cytes and endothelium-related cells demonstrate high myogenic potential in culture and in vivo. Allogeneic 
myoblasts transplanted into Duchenne muscular dystrophy (DMD) patients have been, in early trials, largely 
inefficient owing to immune rejection, rapid death, and limited intramuscular migration—all obstacles that 
are now being alleviated, at least in part, by more efficient immunosuppression and escalated cell doses. As an 
alternative to myoblast transplantation, stem cells such as mesoangioblasts and CD133+ progenitors adminis-
tered through blood circulation have recently shown great potential to regenerate dystrophic muscle.
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INTRODUCTION
From the time of its initial description in 1961, the satellite cell, 
lying on the plasmalemmal surface of the muscle fiber but beneath 
the basement membrane surrounding the fiber,1 was credited with 
the function of the cell responsible for the growth and maintenance 
of skeletal muscle, yet it was not proposed that it was, indeed, a stem 
cell. The gathering of formal evidence that satellite cells are a type 
of stem cell has been greatly hampered by the fact that the prin-
cipal defining feature, their anatomical relationship to the muscle 
fiber, could be established unequivocally only by electron micros-
copy. However, over the past few years, a number of markers have 
been described that identify at least the majority of satellite cells. 
As a result, it has been possible to investigate the functions of this 
class of cells far more thoroughly. The consensus from a number 
of studies using these new markers has largely confirmed the ini-
tial proposition that the satellite cell is the principal, and possibly 
sole, source of muscle regeneration in the adult mouse.2–4 At the 
same time, it has become clear that cells can occasionally enter the 
satellite cell position from other sources, in particular from the 
bone marrow, and participate to some extent in the regeneration 
of skeletal muscle fibers. When first discovered, this phenomenon 
caused much excitement because it held the promise of systemic 
delivery of myogenic cells to all the muscles of the body. Thus far, 
however, the efficiency of this mechanism has not approached that 
of the better-known mechanism of myogenesis based on the satel-
lite cell. Furthermore, recent years have seen the partial identifi-
cation and characterization of multi-lineage stem cells derived in 
culture from numerous adult tissues. The bone marrow–derived 
MSC (mesenchymal stem cell, or marrow stromal cell) can differe-
ntiate into mesodermal cells, including myoblasts,5–8 and adult 
tissues host cells that can also contribute endodermal and ectoder-
mal cell lineages.9–12 A rare subset of multipotent adult progenitor 
Correspondence: Johnny Huard, Departments of Orthopaedic Surgery, Molecular Genetics, and Biochemistry, University of Pittsburgh, School of  
Medicine, Stem Cell Research Center, Children’s Hospital of Pittsburgh, 4100 Rangos Research Center, 3460 Fifth Avenue, Pittsburgh,  
Pennsylvania 15213, USA. E-mail: jhuard@pitt.edu
© The American Society of Gene Therapy review
Molecular Therapy  vol. 15 no. 5, 867–877 may 2007 867
868 www.moleculartherapy.org  vol. 15 no. 5 may 2007  
© The American Society of Gene TherapyStem and Progenitor Cells in Skeletal Muscle
cells, initially identified in adult bone marrow, was assumed to 
account for this multi-lineage potential.13 Multipotent stem cells 
now appear to be broadly distributed, if not ubiquitous, within 
developed tissues; progenitor cells resembling mesenchymal stem 
cells have since been identified in the human umbilical cord,13–15 
and multipotent adult progenitor cell–like cells are present in 
mouse brain,13 pancreas,16 and skin dermis,17 as well as in human 
skin18 and white adipose tissue (Table 1).19
In this article, we first review current knowledge of the cellular 
and molecular biology of satellite cells. We then digest informa-
tion pertaining to the myogenic potential of alternative adult 
multi-lineage progenitor cell populations, emphasizing those 
recently isolated from the skeletal muscle itself, such as side- 
population (SP) cells, CD133+ progenitors, and muscle-derived 
stem cells (MDSCs). Owing to the growing evidence that at least 
some of these adult multipotent cells are ultimately derived from 
blood vessel walls, we have also described both the potential for 
and the interest in myogenesis of mesoangioblasts as well as pro-
spectively purified pericytes, endothelial cells, and myo-endothelial 
cells. The sum of essential knowledge of satellite cells and less con-
ventional myogenic cells has been, finally, put in the perspective of 
therapy, principally for Duchenne muscular dystrophy (DMD).
THE SATELLITE CELL, A PROFESSIONAL 
PROGENITOR CELL IN SKELETAL MUSCLE
Satellite cell distribution in developed  
skeletal muscle
In adult skeletal muscle, satellite cells reside beneath the basal 
lamina of muscle, closely juxtaposed to muscle fibers, and make up 
2–7% of the nuclei associated with a particular fiber. Satellite cells 
are normally mitotically quiescent, but are activated (i.e., enter 
the cell cycle) in response to stress induced by weight bearing or 
by trauma such as injury.20 The descendants of activated satellite 
cells, called myogenic precursor cells, or myoblasts, undergo mul-
tiple rounds of division before fusion and terminal differentiation. 
Satellite cells are distinct from their daughter myogenic precursor 
cells by biological, biochemical, and genetic criteria.21 Activated 
satellite cells also generate progeny that restore the pool of quies-
cent satellite cells. Although it is clear that the satellite cell is the 
main source of myogenic cells in day-to-day maintenance of skel-
etal muscle, it also seems to be the case that satellite cells can move 
between adjacent muscle fibers and must, therefore, spend some 
time in the interstitial space during both growth and regenera-
tion.22,23 Currently, we have no estimate of the proportion of the total 
myogenic population that occupies this interstitial niche, and it is 
 possible that investigation of the dynamics of this exchange between 
satellite cells and the interstitial myogenic cells will resolve some 
of the questions about interstitial myogenic stem cells. Their lack 
of immortality, as well as their key physiological role in normal 
post-natal growth of muscle fibers and regeneration after injuries, 
has made them a unique cell population for cell transplantation 
protocols that employ cells as gene delivery vehicles or as a source 
of cells for tissue build-up (see section Myoblast Transplantation 
As a Therapy for DMD).
Molecular markers of satellite cells
Although there are some marginal discrepancies among the 
 individual markers as to the populations of cells identified as 
 satellite cells, there is broad overall agreement that the majority 
of quiescent satellite cells in the mouse express low levels of Myf5, 
and most are positive for Pax7,24 M-cadherin,25,26 and CD34.4,27 
Among these, as detailed below, Pax7 seems to be crucial; 
although expression of this gene is not required for formation and 
development of pre-natal muscles,24 it is required for persistence 
of the satellite cell population during post-natal life,28,29 Satellite 
cells also express vascular cell adhesion molecule-1 (VCAM-1),30 
c-met (receptor for hepatocyte growth factor), neural cell adhe-
sion molecule-1 (also known as CD56),20 Foxk1,31 and syndecans 
3 and 4.32 Several additional novel genes have been recently iden-
tified, including IgSF4, neuritin, Hoxc10, TcR-β, Klra18, Itm2α, 
G0S2, and MEGF10,  that are expressed in satellite cells in vivo but 
are not expressed by primary myoblasts.33 It has been previously 
reported that some of these markers are expressed at different lev-
els between quiescent and activated satellite cells.34
In humans, the satellite cell markers do not fully correspond to 
those in the mouse. CD34 does not mark satellite cells in human 
muscle, and M-cadherin is not so consistent a marker of human 
as of mouse satellite cells. Among the more reliable markers of 
satellite cells in human muscle is neural cell adhesion molecule 
(CD56), which, however, also marks lymphocytes that may enter 
degenerating muscle in large numbers.35
Molecular control of satellite cell ontogeny  
and function
Early experiments using quail–chick chimeras suggested that sat-
ellite cells were derived from the somite.36 Recent experiments 
support this work and indicate that the progenitors of satellite cells 
originate in embryonic somites as Pax3/Pax7-expressing cells.37,38 
However, as detailed below, studies by De Angelis et al. and 
others provided evidence that satellite cells may also be derived 
from cells associated with the embryonic and adult vasculature.39 
In the adult, results from several laboratories support the notion 
that satellite cells can be derived from so-called adult stem cells 
during regeneration.40–42
The maintenance of satellite cell numbers in aged muscle after 
repeated cycles of degeneration and regeneration has been inter-
preted to support the notion that satellite cells possess an intrin-
sic capacity for self-renewal.20 Asymmetric distribution of Numb 
protein in daughters of satellite cells in cell culture has been impli-
cated in the asymmetric generation of distinct daughter cells for 
self-renewal or differentiation.43 However, whether satellite cells 
are true stem cells or, alternatively, are de-differentiated myo-
blasts44 remains unresolved.
Pax7 and the Pax family of developmental-control transcription factors. 
The paired-box family of transcription factors (Pax1–9) has 
important functions in the regulation of the development and dif-
ferentiation of diverse cell lineages during embryogenesis.45 Pax7 
and the closely related Pax3 gene are paralogs with almost iden-
tical amino acid sequences and partially overlapping expression 
patterns during mouse embryogenesis.46,47 Notably, Pax3 plays an 
essential role in regulating the developmental program of MyoD-
dependent migratory myoblasts during embryogenesis.48,49 More 
recently, Pax3+/Pax7+ progenitors originating in the embryonic 
somite have been suggested to be the precursors of satellite cells 
in adult muscle.37,38
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muscle express Pax7 and give rise to skeletal myoblasts. In con-
trast, CD45+/Sca1+ cells from regenerating Pax7–/– muscle do 
not undergo myogenic progression unless exposed to Wnt pro-
teins.42 Retroviral expression of Pax7 in CD45+/Sca1+ cells from 
uninjured muscle induced the formation of myogenic progeni-
tors expressing Myf5 and MyoD, which differentiated into myo-
genin and myosin heavy chain–expressing myocytes.55 Together, 
these results demonstrate that Pax7 is required for the myogenic 
specification of muscle-derived adult stem cells during regenera-
tive myogenesis.42,55 It is important to note that, although atypical 
myogenic cell progenitors have the proven potential to participate 
to some degree in muscle regeneration under conditions of severe 
trauma, these experiments, when taken together, strongly support 
the contention that, under physiological conditions, the growth 
and regeneration of skeletal muscle is mediated largely, if not 
exclusively, by muscle satellite cells.62
In addition, numerous growth factors such as fibroblast 
growth factor 6, bone morphogenetic protein, and NO have been 
suggested to play roles in stimulating satellite cell activation.21 
Nevertheless, the precise molecular mechanisms regulating satel-
lite cell function remain poorly understood.
Myoblast transplantation as a therapy for DMD
Myoblast transplantation is a possible treatment for several mus-
cular dystrophies. The initial demonstration that myoblast trans-
plantation could restore the expression of dystrophin in  nude/mdx 
mouse muscle fibers came as early as 1989.63 This promising result 
triggered a rapid series of clinical trials of myoblast transplanta-
tion to DMD patients.64–71 However, these clinical trials produced 
either negative or very limited positive results. Tremblay’s group 
reported the presence of dystrophin-positive muscle fibers in a 
few patients, but was not able, at the time, to rule out the pos-
sibility that these were revertant muscle fibers, as the mutation 
in the patients had not been identified.64,67 Karpati’s group used 
cyclophosphamide as an immunosuppressive agent;68 however, 
experiments on mice in subsequent years demonstrated that this 
anti-tumor drug killed the transplanted myoblasts, as well as 
any other rapidly proliferating cells.72 Gussoni et al. reported the 
detection, by reverse-transcriptase polymerase chain reaction, 
of the normal messenger RNA, but this did not translate into an 
increase in the percentage of dystrophin-positive fibers following 
myoblast transfer therapy.69 Mendell’s group reported the presence 
of 10% dystrophin-positive fibers in one patient.71 These fibers 
were definitively of donor origin as they were identified with a 
dystrophin monoclonal antibody detecting an epitope encoded by 
an exon deleted in the patient’s genome.
Pax7 and Pax3 proteins bind similar, if not identical, sequence-
specific DNA elements, suggesting that they regulate similar sets 
of target genes.50 Furthermore, increased expression and gain-of-
function mutations in both Pax3 and Pax7 are associated with 
the development of alveolar rhabdomyosarcomas, indicating 
that the two molecules regulate similar activities in the myo-
genic program.51 Although the Pax3 and Pax7 proteins are struc-
turally similar, analysis of null mutations in mice indicates that 
they are required for the development of a number of distinct 
cell lineages24,52–54 and appear to have only redundant roles in 
myogenesis.24,28,37,38,55
Splotch (Sp) mice, lacking a functional Pax3 gene, do not 
survive to term and fail to form limb muscles owing to impaired 
migration of Pax3-expressing cells originating from the somite.53,56 
Compound mutant Sp/Myf5–/– mice do not express MyoD in 
their somites, suggesting that Myf5 and Pax3 function upstream 
of MyoD in myogenic determination.49 Forced expression of Pax3 
induces MyoD expression and subsequent myogenesis in non-
muscle tissues in avian embryos.48 However, ectopic expression of 
Pax3 in C2C12 myoblasts efficiently inhibits myogenic differen-
tiation.57 Co-expression of MyoD and Pax3 is not observed in the 
mouse myotome.58 Therefore, Pax3 was suggested to function as an 
indirect upstream factor that induced migration or other cellular 
changes to facilitate subsequent induction of MyoD transcription.59 
Contrary to this notion, a Pax3–FKHR fusion gene was observed 
to activate many muscle regulatory genes, including Myf5, follow-
ing expression in NIH-3T3 cells.60 These data, together with the 
co-expression of Pax3 and Pax7 in somite-derived pro-satellite 
cells,37,38 suggest that Pax3 mediates the migratory phase of the lin-
eage, whereas Pax7 is required to achieve myogenic potential.
Pax7 is required for the myogenic specification of satellite 
cells. Using representational difference analysis, the paired-box 
transcription factor Pax7 has been cloned as a gene specifically 
expressed in the satellite cell myogenic lineage.24,33 Pax7 is specifi-
cally expressed in satellite cells in adult muscle and their daughter 
myogenic precursor cells in vivo and primary myoblasts in vitro. 
Cell culture and electron microscopic analysis indicated ablation 
of satellite cells in Pax7–/– skeletal muscle. Fluorescence-activated 
cell sorting/Hoechst analysis demonstrated that the proportion of 
muscle-derived SP cells, a putative adult stem cell population fur-
ther described below, was unaffected. These results demonstrate 
that satellite cells and muscle-derived SP (side population) cells 
represent distinct cell populations and reveal an essential role for 
Pax7 in specifying the satellite cell myogenic lineage functioning 
upstream of the MyoD family of bHLH factors (Figure 1).24,42,55
An extensive analysis of Pax7–/– mice has confirmed the pro-
gressive ablation of the satellite cell lineage in multiple muscle 
groups.24,28 Small numbers of Pax7-deficient cells do survive in 
the satellite cell position, but these cells arrest and die upon enter-
ing mitosis. Pax7–/– muscles are reduced in size, the fibers contain 
approximately 50% of the normal number of nuclei, and fiber 
diameters are significantly reduced. Together, these data confirm 
an essential role for Pax7 in regulating the myogenic potential of 
satellite cells.61
In previous studies, the potential of atypical non-satellite cell 
progenitors to participate in muscle regeneration has been inves-
tigated. CD45+/Sca1+ cells purified from regenerating wild-type 
Figure 1 Pax7 has an essential role in regulating the myogenic poten-
tial of muscle satellite cells. In the absence of Pax7, satellite cells die 
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In the years that followed these initial trials, several research 
teams identified three problems that were responsible for the 
limited results observed: (i) at least 75% of the transplanted 
myoblasts die in the first 3 days after transplantation;73–75 
(ii) myoblasts do not migrate more than 200 μm away from the 
intramuscular injection trajectory;76 and (iii) if immunosup-
pression is not adequate, the myoblasts are rapidly rejected in 
less than 2 weeks.77 Moreover, cyclosporine, which was used for 
immunosuppression in several clinical trials, induces apoptosis 
of the myoblasts at the time of their differentiation.78,79 There are 
now some solutions to overcome these problems. The rapid death 
of a large percentage of myoblasts can be compensated for by the 
transplantation of a high number of cells. Indeed the transplanta-
tion of 30 million cells per mm3 produced very good results in 
monkeys.76 The low migration distance of myoblasts requires a 
high number of adjacent intramuscular injections to obtain good 
transplantation results in monkeys. Immunosuppression with 
FK506 (Tacrolimus or Prograf®; ASTELLAS Pharma, Deerfield, 
IL, USA) permitted Kinoshita et al.80,81 to obtain very good trans-
plantation results not only in mice but also in monkeys. Other 
technologies, such as the modulation of MyoD expression82 and 
the use of matrix metalloproteinase,83 have also been used to 
improve myoblast migration within the injected muscle. Simi-
larly, it has been observed that increased muscle regeneration and, 
potentially, myoblast migration often occur in the environment 
of the irradiated muscle, suggesting that factors released with the 
irradiated muscle can eventually be used to improve the success 
of myoblast transfer therapy.84
These solutions are not ideal, but they nevertheless permit-
ted the restoration of dystrophin expression in 26–30% of mus-
cle fibers in a recent clinical trial.85–87 These are the best results 
obtained in DMD patients by any therapeutic approach so far. 
These results in DMD patients required a high number of injec-
tions (i.e., 100 injections per cm2 of muscle surface). Although this 
procedure seems scary at first, it was very well tolerated by mon-
keys and the 11 patients who have so far received such transplan-
tations under local anesthesia. One patient has received a total of 
4,000 intramuscular injections without any complication.87 This 
patient indicated that the procedure was not any worse than going 
to the dentist, and that a simple over-the-counter medication was 
sufficient to control the pain. There was no infection or other 
complication associated with the procedure. Given the severity of 
this disease, and the fact that there is no alternative therapy, this 
treatment seems acceptable to most patients.
Successful myoblast transplantation in mice, monkeys, and 
humans currently requires sustained immunosuppression therapy 
with FK506. This agent may induce adverse effects in patients 
(nephrotoxicity, diabetes, increased risk of cancer) if used on an 
ongoing, long-term basis. Two possible alternative solutions exist 
to avoid these problems. The first solution is to induce specific 
immunological tolerance toward donor myoblasts, as has already 
been done in mice using two different protocols to induce mixed 
chimerism and central tolerance.88,89 The second of these proto-
cols used no more than two drugs (cyclophosphamide and treo-
sulfan), which have already been approved for clinical use and 
do not require immunosuppressive therapy. A second alterna-
tive to sustained immunosuppression therapy is the transplan-
tation of genetically modified autologous myoblasts. Successful 
 transplantation of myoblasts genetically altered with a lentiviral 
vector containing the micro-dystrophin gene has been recently 
reported in mice and in monkeys.90 Introduction of the full dys-
trophin gene in myoblasts with an adeno/adeno-associated virus 
vector is, according to other reports, also possible.91,92 In addition, 
it is feasible to skip one exon following genetic modification of 
myoblasts with a lentivirus coding for an appropriate short hair-
pin RNA. The transplantation of autologous, genetically corrected 
myoblasts is potentially limited by the gradual senescence of the 
satellite cells in patients as they age. A possible solution to this 
problem would be to derive myoblasts from other autologous plu-
ripotent stem cells such as those found in adipose tissue93 or from 
the other stem cells discussed in this review.
Research to increase the migration distance of myoblasts injec-
ted into muscle is still ongoing.94,95 Although this limited distance is 
a problem, intramuscular delivery of cells does prevent complica-
tions associated with systemic delivery (i.e., the risk of embolism in 
the lungs, heart, brain, kidneys, and liver). The risks associated with 
repeated, localized intramuscular injections may, thus, be lower 
than those associated with systemic delivery of stem cells.
MULTIPOTENT STEM CELLS IN SKELETAL MUSCLE 
DEVELOPMENT AND REPAIR
Muscle SP cells as a source of myogenic stem cells
SP cells were first isolated from mouse skeletal muscle96,97 by adapt-
ing a method optimized for the purification of bone marrow SP 
cells.98 Muscle SP cells are heterogeneous and differ from bone 
marrow SP cells with respect to expression of surface antigens.96,99 
The heterogeneity of SP cells increases when low Hoechst dye 
concentrations are used for the isolation procedure, as cells that 
would normally be within the main population fall within the SP 
gate.100 The main population is thought to be enriched in lineage- 
committed cells.98 When isolated using high Hoechst dye concen-
trations, the majority of mouse muscle SP cells (>90%) are positive 
for stem cell antigen-1 (Sca-1) and are negative for the hemato-
poietic SP markers CD45, CD43, and c-kit.100 Genes expressed 
by murine bone marrow and skeletal muscle SP cells have been 
studied, highlighting transcriptional similarities and differences 
between these two tissue-specific “stem” cell populations.101
Early experiments demonstrated that muscle SP cells have the 
ability, upon intravenous injection, to engraft in the skeletal mus-
cle of mice with muscular dystrophy,96 whether or not host mice 
had been lethally irradiated.102 When host mice were lethally 
irradiated, muscle SP cells appeared to provide short-term 
hematopoietic reconstitution of the bone marrow.96 Subse-
quent studies have indicated that the hematopoietic potential 
of muscle SP cells resides in a small fraction that expresses the 
hematopoietic cell marker CD45, whereas the “myogenic” frac-
tion is CD45-negative.103,104
With regard to their position in the myogenic cell lineage, 
muscle SP cells appear to be different from satellite cells. First, 
muscle SP cells are present in Pax7–/– mice, which exhibit a severe 
deficiency in satellite cells.24 Second, muscle SP cells cultured 
in vitro adopt a myogenic fate and express markers that are pres-
ent on quiescent and activated satellite cells upon culture with 
myogenic cells.40 Finally, after injection into diseased or injured 
muscle in vivo, muscle SP cells give rise to Myf5-positive cells or 
to Pax7-positive, desmin-positive myogenic cells—all markers 
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that are also expressed by activated or quiescent satellite cells.102,105 
The developmental origin of muscle SP cells appears to be, at 
least partly, located within the somites, as demonstrated via ret-
roviral somite labeling in chick–quail chimeras and analyses of 
Pax3–green fluorescent protein transgenic mice.106 Further, it 
appears that muscle SP cells do not receive a contribution, at least 
post-natally, from cells within the bone marrow, as trafficking 
from the bone marrow to muscle SP cells has not been detected 
after bone marrow transplantation followed by cardiotoxin treat-
ment of the host muscle.107
Muscle SP cells are still under investigation to better under-
stand their potential for targeting dystrophic muscle after injec-
tion into the circulation. Recent studies have demonstrated that 
cultured muscle SP cells (as opposed to freshly isolated SP cells) 
can more efficiently engraft in dystrophic muscle after delivery via 
the femoral artery.108 Although the levels of engraftment reported 
thus far are not therapeutically significant, promising studies are 
ongoing to further test the efficacy of serial intra-arterial injections 
and to identify the molecule(s) that may be responsible for the 
efficient extravasation of SP cells from the circulation to dystro-
phic skeletal muscle (Bachrach et al., manuscript in preparation). 
Finally, muscle SP cells have also been isolated from human 
muscle and are being studied to determine their possible role in 
this tissue.109 In fetal skeletal muscle, recent evidence suggests that 
muscle SP cells may act as paracrine cells, secreting factors that 
might promote the proliferation of other myogenic cells located 
nearby.110 It has recently been found that human fetal muscle 
SP cells express high levels of bone morphogenetic protein-4, 
which stimulates the proliferation of Myf5+/BMPR1A+ myogenic 
cells.110 This proliferation can be inhibited by gremlin, a known 
bone morphogenetic protein-4 antagonist that is highly expressed 
by muscle main population cells.110
In summary, muscle SP cells are a rare cell type within skeletal 
muscle and share markers with mesoangioblasts111 and MDSCs.112 
Future studies on muscle SP cells will address the relationships 
between these cells and other progenitors found in muscle. By 
consolidating the ties between different “stem” cells within muscle, 
it will be possible to merge knowledge on how to better propagate 
and manipulate these cells, with the goal of using them efficiently 
for therapeutic applications.
Mesoangioblasts as a potential source  
of stem cells to regenerate skeletal muscle
Among different types of mesodermal stem cells recently iden-
tified and characterized to different extents are mesoangioblasts. 
Mesoangioblasts were first identified in the wall of the mouse 
embryonic dorsal aorta as cells expressing early endothelial (as 
well as several pericyte) markers39 that were able to proliferate 
extensively in vitro and, in due course, differentiate into different 
types of solid mesoderm.113 Mesoangioblast-like cells were later 
isolated from vessels of post-natal tissues in the mouse, rat, dog, 
and human. Post-natal cells generally express pericyte rather than 
endothelial cell markers but are otherwise similar to their embry-
onic counterparts in terms of proliferation and differentiation 
potency. It is hypothesized that dog and human cells proliferate to 
a limited extent and undergo senescence at variance with rodent 
cells, which eventually become aneuploid and immortal. When 
wild-type or dystrophic, genetically corrected mesoangioblasts 
were delivered intra-arterially to dystrophic muscle of α-sarco-
glycan-null mice (a model for limb girdle muscular dystrophy), 
they induced a dramatic functional amelioration of the dystro-
phic phenotype.114 This was due to the widespread distribution 
of donor cells through the capillary network and to an intrinsic 
defect of proliferation in the resident satellite cells, a situation that 
created a selective advantage for the injected donor cells.
To proceed to clinical experimentation it was considered to 
be crucial that delivery and muscle homing of mesoangioblasts 
be optimized to characterize human cells in depth and that 
the protocol be tested in a large-animal model. Recently, it was 
reported that enhancing delivery of mesoangioblasts leads to 
the complete reconstitution of downstream skeletal muscles in 
α-sarcoglycan-null dystrophic mice. Mesoangioblasts, exposed 
in vitro to either stromal cell derived factor-1 or tumor necrosis 
factor-α showed enhanced transmigration in vitro and migration 
into dystrophic muscle in vivo. Transient expression of α-4 integ-
rins or l-selectin also produced a several-fold increase in migra-
tion both in vitro and in vivo. Thus, combining stromal derived 
factor-1 with expression of α-4 integrin resulted in reconstitution 
of more than 80% of α-sarcoglycan-expressing fibers, with a five-
fold increase in efficiency over control cells.115
Similar cells could be isolated from blood vessels of human 
post-natal skeletal muscle that expressed markers for pericytes, 
such as alkaline phosphatase, and that differentiated into myo-
tubes in vitro with high efficiency. When transplanted into severe 
combined immunodeficiency (SCID) mdx mice, human mesoan-
gioblasts generate numerous fibers expressing human dystrophin. 
Cells similarly isolated from DMD patients and engineered to 
express human mini-dystrophin also gave rise to many dystro-
phin-positive fibers in vivo.116 Finally, arterial delivery of wild-
type canine mesoangioblasts in dystrophic dogs led to extensive 
recovery of dystrophin expression and amelioration of muscle 
morphology and function.117 Together, these data contribute to a 
detailed characterization of mesoangioblasts and lay the founda-
tion for future clinical experimentation. 
Repairing skeletal muscle with CD133+  
progenitor cells
As mentioned above, attempts to repair muscle damage in DMD 
patients by transplanting myogenic progenitors directly into 
muscles faced problems of cell survival and limited intramuscular 
migration. The delivery of myogenic stem cells to the sites of mus-
cle lesions via the systemic circulation is a potential alternative 
approach to treating this disease, but intravenously injected cells 
may be trapped in other organs (e.g., liver, spleen, lung) so that only 
a small portion enter muscle capillary circulation and migrate into 
dystrophic muscle. Recent works support the idea that stem cells 
may reach the site of muscle regeneration and contribute to mus-
cle repair as well as replenish the satellite cell pool after arterial 
injection, suggesting that this technique is particularly suited for 
treating muscle dystrophy.114,115,118,119 The success of this protocol 
was largely due to the widespread distribution of donor stem cells 
through the muscle capillary network, a distinct strategic advan-
tage over previous approaches. The molecular pathways involved 
in muscle stem cell homing should be carefully considered in 
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any attempt to treat DMD patients by arterial delivery. Dystro-
phic muscle damage results in the release of various substances, 
including intracellular proteins, cytokines, and chemokines, ulti-
mately resulting in an inflammatory response.21,120–123 This condi-
tion creates a microenvironment that may regulate the expression 
of chemo-attractant receptors (e.g., l-selectin and very late anti-
gen-4) and stimulate stem cell homing.96,115,119,124 Sca-1+/CD34−/l-
selectin+ MDSCs did “home” to the muscle tissues; in fact, these 
cells were prevalently found to adhere firmly and cross the endo-
thelium of mdx dystrophic muscles after intravenous injections. 
Muscle homing was probably related to the high expression of 
l-selectin ligands on the vessels of inflamed muscles, as is the case 
in dystrophic muscles.125,126 Of particular significance, endothe-
lium from dystrophic muscle expresses the mucosal addressin cell 
adhesion molecule-1, which is a ligand for the l-selectin expressed 
selectively at venular sites on chronically inflamed endothelium in 
muscle dystrophy. Interestingly enough, only blood vessels from 
young mdx mice express mucosal addressin cell adhesion mol-
ecule-1, whereas blood vessels from older mice were observed to 
have down-regulated mucosal addressin at their surface. 
Freshly isolated human CD133+ cells express CD44, lym-
phocyte function-associated antigen-1, P-selectin glycoprotein 
ligand-1, very late antigen-4, and l-selectin, a pattern of adhe-
sion molecules defining cells potentially able to migrate through 
the blood vessel wall. When injected into the circulation of dys-
trophic scid/mdx mice, the CD133+ cells contributed to muscle 
repair and the replenishment of the satellite cell pool after arte-
rial injection.119 Human dystrophin expression was significantly 
increased when muscle exercise was performed 24 hours before 
the arterial injection of human CD133+ cells. In these experi-
ments, muscle exercise produced acute inflammation in the dys-
trophic muscle, massively increasing the expression of VCAM-1 
on murine endothelium. However, low expression of VCAM-1 
in vessels of unexercised dystrophic muscle was not sufficient to 
mediate efficient recruitment of CD133+ cells in this experimen-
tal model (Figure 2). Intravital microscopy analysis confirmed 
that CD133+ stem cells were able to roll and firmly adhere in 
the dystrophic vessels of scid/mdx mice as a result of the inter-
action between VCAM-1 and very late antigen-4 (Figure 2). 
Development of methods to manipulate the expression of 
VCAM-1 and its ligands might improve muscle stem cell 
homing and open new therapeutic perspectives for muscular 
 dystrophy patients.
Isolation of stem cells from skeletal muscle via  
the pre-plate technique
A modified pre-plate technique was used to isolate various popu-
lations of muscle-derived cells from mice, including a population 
of early myogenic progenitor cells. In fact, through this pre-plate 
technique, which separates myogenic cells based on their adher-
ence to collagen-coated flasks, a population of early myogenic pro-
genitor cells was isolated from the late pre-plate fraction of cells 
and a population of more committed myogenic cells was isolated 
from an earlier fraction of cells as observed by others. On the basis 
of their marker profiles (stem cell and myogenic cell marker pro-
files) as well as their proliferation/fusion behavior in vitro, earlier 
fraction of cells are likely a population of satellite cells, whereas the 
long-term proliferating cells derived from the late pre-plate frac-
tion of cells appear to be MDSCs.127, 128, 129, 130
The transplantation of these early myogenic cells (MDSCs) 
into the skeletal muscle of mice yields a better outcome than the 
transplantation of late myogenic progenitor cells, such as satel-
lite cells. Experiments have been also conducted to determine 
the mechanism by which mouse MDSCs display an improved 
regeneration capacity in skeletal muscle (when compared with 
satellite cells). The ability of MDSCs to proliferate in vivo for an 
extended period of time—combined with their strong capacity for 
self-renewal, their multi-lineage differentiation (particularly into 
blood vessel cells), and their immune privilege—reveals, at least 
in part, the basis for the improvements observed after transplanta-
tion of these cells in skeletal muscle.127 The use of such early myo-
genic progenitor cells might significantly improve the outcome of 
muscle cell–mediated therapies. It has been recently demonstrated 
that superior survival and proliferation occur after transplanta-
tion of myogenic cells derived from the pre-plate technique when 
the cells are obtained from adult mice, as opposed to newborn 
mice, suggesting that the age of the animals can influence the abil-
ity of myogenic cells to regenerate skeletal muscle.131 Similarly, we 
have recently observed that the sex of the animals from which we 
derived MDSCs, as well as the sex of the host animals selected 
as recipients for cell transplantation, can influence the success of 
cell transplantation.132 In fact, it was determined that female cells 
have a higher regeneration index than male cells and that female 
hosts are better recipients for optimal muscle regeneration after 
MDSC transplantation than male hosts.132 The sex of the cells and 
the host may explain reported discrepancies in terms of regener-
ating potential of MDSCs obtained by different research groups 
where either male host animals were used133 or male MDSCs were 
utilized because of the need to make use of fluorescent in situ 
hybridization to track male cells injected into female hosts.134,135 















Figure 2 Recruitment of stem cells in inflamed murine muscle endo-
thelium is mediated by adhesion molecules. The expression of high 
levels of VLA-4 on human CD133+ stem cells and up-regulation of the 
endothelial vascular cell adhesion molecule 1 (VCAM-1) in dystrophic 
inflamed vessels are critical for the capture and migration of the injected 
stem cells. (a) In murine muscle that was not inflamed, the interaction 
of P-selectin glycoprotein ligand-1 (PSGL-1) (expressed on the CD133+ 
stem cells) and the corresponding endothelial receptor P-selectin con-
tributes to rolling but is not relevant for the capture and migration of 
the CD133+ stem cells. (b) However, dystrophic inflamed endothelium 
enriched in VCAM-1 adhesion molecules mediates frequent rolling 
events and the migration of the CD133+ stem cells.
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as important variables that may influence the regenerating poten-
tial of a given cell population.
Early myogenic progenitor cells (MDSCs) isolated from 
mice engraft better than late myogenic progenitor cells (satellite 
cells) after intracardiac implantation in both cardiomyopathic 
and infarcted hearts of mice.136,137 In fact, when compared with 
satellite cells, mouse MDSCs display superior engraftment in 
infarcted hearts because they survive better and favor angiogen-
esis, as observed in skeletal muscle.127,136
Myogenic cells in the walls of human blood vessels
The muscle-derived stem cells described in the above sections 
are but one example among several types of multipotent cells 
described in adult, developed, human and mouse organs. With-
out exception, and as described above in the case of MDSCs, all 
these multi-lineage cells have been isolated retrospectively from 
cultured adult tissues. Therefore the embryonic origin, identity, 
and, primarily, the anatomic localization of these stem cells within 
adult tissues remains unknown.
Some of us have recently attempted to characterize non- 
lineage-restricted adult human stem cells, assuming that the diversely 
designated mesenchymal stem cells, multipotent adult progenitor 
cells, and MDSCs are all derived, upon long-term culture, from 
the same original, omnipresent stem cell. The walls of blood ves-
sels have emerged as a possible repository for such pan-organ stem 
cells, as almost all tissues are vascularized. As a subset of MDSCs 
express endothelial cell markers and promote neoangiogenesis 
through differentiation into endothelial cells via vascular endothe-
lial growth factor secretion,127,136,137 it was assumed that these cells 
are interrelated with endothelial cells. The existence of blood ves-
sel–associated stem cells has also been supported by the description 
and characterization of mesoangioblasts, as previously described 
(see section entitled “Mesangioblasts as a potential source of stem 
cells to regenerate skeletal muscle”), and by the demonstration that 
definitive hematopoietic stem cells emerge in the embryo from a 
specialized subset of hemogenic vascular endothelial cells.138,139
Cells with high myogenic potential in human adult skeletal 
muscle are found within vascular endothelium. By multi-
color immunostaining and confocal microscopy analysis of 
human skeletal muscle sections, it was observed that a subset of 
satellite cells co-express endothelial cell antigens. The existence 
of this novel population of myo-endothelial cells was further 
documented by flow cytometry. These cells, which represent less 
than 0.5% of the total skeletal muscle population, can be con-
veniently typified as CD56+/CD34+/CD144+/CD45– and sorted 
accordingly to homogeneity. To assay the myogenic potential of 
this novel cell subset, these myo-endothelial cells and, in paral-
lel, genuine CD56+CD34−CD144−CD45− myogenic cells and 
CD34+/CD144+/CD56−/CD45− endothelial cells were sorted 
and injected intramuscularly into SCID mouse skeletal muscles 
that had been injured previously by cardiotoxin injection. Our 
study revealed that both muscle endothelial cells and myo-endo-
thelial cells are able, as is the case with conventional myogenic 
cells, to regenerate muscle fibers within the injured muscle. These 
experiments demonstrated that muscle vascular endothelial cells 
and, most notably, a novel subset of cells with an overlapping 
phenotype between myogenic and endothelial cells, are endowed 
with a regenerating potential in skeletal muscle to a level simi-
lar and even higher than myogenic cells (B. Zheng, B. Cao, 
M. Crisan, B. Sun, G. Li, A. Logar et al., manuscript submitted).
These results have suggested the existence of a developmental 
relationship between vascular cells and myogenic cells. In sup-
port of this hypothesis, total muscle cells or sorted CD56+ myo-
genic cells cultured under conditions that favor endothelial cell 
growth (endothelial cell growth medium-2, (Cambrex Corp., 
East Rutherford, NJ)) have yielded large numbers of cells co-
expressing myogenic and endothelial cell markers (B. Zheng, 
B. Cao, M. Crisan, B. Sun, G. Li, A. Logar et al., manuscript 
 submitted). Interestingly, myogenic potential does not seem to 
be restricted to muscle-derived endothelial cells, as vascular 
endothelial cells purified from adult human pancreas and adi-
pose tissue can also support myofiber regeneration (M. Crisan, 
B. Sun, L. Casteilla, M. Gavina, S. Yap, C. Norotte et al., manu-
script submitted; S. Yap, M. Crisan, B. Sun, J. Huard, L. Casteilla, 
J.-P. Giacobino et al., manuscript submitted). 
Myogenic potential of human perivascular cells. Pericytes 
closely encircle endothelial cells in capillaries and microvessels.140 
These cells regulate microvessel contractility, and can inhibit the 
division of endothelial cells (reviewed in ref. 141). Pericytes are 
also suspected to include progenitors of chondrocytes, adipocytes, 
osteocytes, and odontoblasts.142–144 However, these published 
differentiation experiments were performed only on pericyte- 
containing cultures and not on purified pericytes. Some of us 
aimed to determine whether pericytes are also endowed with myo-
genic potential, using an experimental strategy and tactics similar 
to those described above for endothelial cells. As a prerequisite 
to human pericyte sorting by flow cytometry, we determined, by 
immunohistochemistry, a relevant combination of markers for 
this elusive cell population. Expression of CD146 and NG2 typi-
fies pericytes in all human tissues analyzed. In contrast, pericytes 
do not express endothelial cell antigens such as CD144 (VE- 
cadherin), von Willebrand factor, CD34, CD31, and the Ulex 
europaeus lectin ligand. CD146+/CD34−/CD45−/CD56− peri-
cytes were sorted by fluorescence-activated cell sorting from 
human skeletal muscle and confirmed, by reverse-transcriptase 
polymerase chain reaction analysis, not to include hematopoietic, 
endothelial, and regular myogenic cells.
Sorted pericytes cultured in muscle proliferation medium, and 
then in muscle fusion medium, developed into multinucleated 
myotubes expressing myosin heavy chain. Furthermore, sorted 
pericytes (CD146+/CD45−/CD34−/CD144−/CD56−), myoblasts 
(CD146−/CD45−/CD34−/CD144−/CD56+), and unseparated 
muscle cells all regenerated muscle fibers after injection into the 
cardiotoxin-injured skeletal muscles of SCID-non-obese diabetic 
mice, indicating a muscle-regenerating potential for pericytes 
(M. Crisan, B. Sun, L. Casteilla, M. Gavina, S. Yap, C. Norotte et al., 
manuscript submitted).
Strikingly, pericytes sorted from adult human adipose tis-
sue or pancreas exhibited similar potential to skeletal muscle 
pericytes for generating myotubes in culture and myofibers in 
SCID-non-obese diabetic mouse muscles (S. Yap, M. Crisan, 
B. Sun, J. Huard, L. Casteilla, J.-P. Giacobino et al., manuscript 
submitted). Hypothetically, blood vessel walls would harbor a 
mostly dormant reserve of multi-lineage stem cells that could 
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be recruited in emergency situations, when professional tissue- 
specific progenitors have been exhausted.
Altogether, the results reported above point to the existence 
of a myogenic potential within cells that make up the walls of 
blood vessels, i.e., endothelial cells and pericytes. A rare subset 
of myo-endothelial cells has been additionally identified in skel-
etal muscle that exhibits myogenic potential and may represent 
a developmental intermediate between both lineages. Under 
normal-life conditions, the existence of a physiological role for 
vascular cells in the development and/or regeneration of human 
skeletal muscle remains to be demonstrated, especially in light of 
the fact that a similar myogenic potential is present within peri-
cytes and endothelial cells purified from pancreas, fat, and, pos-
sibly, other tissues. Rather than a restricted myogenic potential, 
pericytes purified from human tissues have exhibited a broader 
ability to differentiate into bone, cartilage, and adipocytes (data 
not shown), in agreement with published preliminary results.142–144 
The quasi-omnipresence of pericytes in the organism suggests a 
pan-organ dissemination of multi-lineage stem cells, which may 
have been the origin of mesenchymal stem cells, multipotent adult 
progenitor cells, MDSCs, and other adult stem cells immortalized 
in culture. It should not be assumed, however, that the sharing 
of surface markers between cell populations indicates that the 
cells are related, as additional behavioral testing should be per-
formed to determine whether a relationship truly exists between 
these various populations of cells. From a practical perspective, 
these novel myogenic progenitors derived from the walls of blood 
vessels appear to be amenable to biotechnological processing. In 
fact, these cells can be sorted to homogeneity by flow cytometry 
from skeletal muscle and even more accessible sources such as 
adipose tissue. Therefore, the transplantation of autologous blood 
vessel–related progenitors could potentially be envisioned as a 
therapy for skeletal muscle diseases.
CONCLUSION
Our understanding of tissue regeneration and repair at adult 
stages remains largely inspired by the advanced knowledge gained 
on the hematopoietic system, in which a hierarchy of increasingly 
 committed blood cell progenitors is dominated by a small subset of 
multipotent stem cells. In contrast, although the ability of skeletal 
muscle, at any stage of post-natal life, to regenerate upon sustained 
physical activity or injury is well documented, intramuscular myo-
genic cells have long been assumed to be restricted to a population 
of late, committed muscle progenitors, namely the satellite cells. 
Considerable progress has been made recently in understanding 
the biology of satellite cells, the ontogeny of which has been traced 
back to paraxial mesoderm, under a molecular control that has 
been largely deciphered. However, although satellite cells remain 
recognized as the primary cells responsible for the regeneration 
of post-natal skeletal muscle, research over the past few years 
has shown that several other cell types, including MDSCs, side- 
population cells, and mesoangioblasts, can display similar behav-
iors in experimental conditions. The (possibly common) origin 
of these stem cell populations and their relationship to satellite 
cells remain largely unknown. Most recent results suggest that 
at least some of these stem cells originate in the walls of muscle 
and non-muscle blood vessels, in which subsets of prospectively 
sorted endothelial and pericyte cell lineage cells are endowed with 
myogenic potential. It remains completely unknown whether 
these novel myogenic cells, which have the potential to give rise 
to other mesodermal cell lineages, play any role in muscle renewal 
in steady-state conditions, or are only recruited in conditions of 
emergency. Although major developments are being made to 
improve the success of myoblast transplantation in DMD patients, 
we believe that such novel cells endowed with strong myogenic 
potential, whatever their normal function in situ, should also 
be considered for the cell-mediated therapy of muscle diseases. 
Although this review has focused primarily on post-natal stem 
cells, we do not exclude the idea that embryonic stem cells, and 
perhaps their progeny, may also be used for muscle regeneration 
and repair. In fact, it has been recently reported that differentiated 
embryonic stem cells transfected with insulin-like growth factor II 
regenerate injured skeletal muscle in a more effective manner than 
undifferentiated embryonic stem cells.145 This study illustrates the 
idea that embryonic stem cells that are genetically engineered to 
express insulin-like growth factor II may represent another cell 
source for cell-based transplantation therapy to repair muscle 
damaged by injury or myopathy, but additional experiments are 
required to further evaluate their muscle-regenerating potential.
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